ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2026-5781

An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modificati…

Published Apr 28, 2026 · catalog updated Jun 17, 2026 · the affected product

Check if you run it

No confirmed exploitation is on record for CVE-2026-5781. EPSS is 0.42%. Act only if a listed version of the affected product is installed.

Gaps on this record

  • No plain product name is stored. The page cannot tell you which product to check.
  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
High8.5
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.42%
Remediation
Advisory link
Affected products
cpe agilonhealth/minerva

An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modification privileges to escalate their privileges by sending an HTTP request with a manipulated 'identifier' field. Successful exploitation of this vulnerability could allow an authenticated user to obtain administrator privileges. It is not possible to escalate privileges through the graphical user interface.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • cpe agilonhealth/minerva3.6.0

How to fix CVE-2026-5781

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2026-5781. EPSS is 0.42%. Act only if a listed version of the affected product is installed.

Which versions are affected?

Compare what you have installed with 3.6.0. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

CWE-285: Improper Authorization. EPSS 0.42%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

No public source repository is identified for this product.

Timeline

Detection, updates, and resolution for this record.

  1. Apr 28, 2026 · NIST NVD

    Detected

    An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modification privileges to escalate their privileges by sending an HTTP request with a manipulated 'identifier' field. Successful exploitation of this vulnerability could allow an authenticated user to obtain administrator privileges. It is no

  2. Jun 17, 2026 · NIST NVD

    Updated

    An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modification privileges to escalate their privileges by sending an HTTP request with a manipulated 'identifier' field. Successful exploitation of this vulnerability could allow an authenticated user to obtain administrator privileges. It is no

Sources

  • CVE.orgVulnerability recordCVE-2026-5781

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2026-5781

    30-day exploitation probability 0.4%

    first.org
  • NIST NVDVulnerability recordCVE-2026-5781

    An authorization vulnerability in MphRx's Minerva V3.6.0, specifically in the '/minerva/moUser/update' endpoint, could allow an authenticated user with user modification privileges to escalate their privileges by sending an HTTP request with a manipulated 'identifier' field. Succ

    nvd.nist.gov

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.